Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909316 | 0.88 | TDP1 (0.58) | TDP1GAASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL5162366 | 0.88 | TDP1 (0.48) | TDP1GAALMNASMN1; SMN2TSHR | |
| SCHEMBL7888553 | 0.88 | L3MBTL1 (0.53) | TDP1TSHRALDH1A1SLC22A12GLS | |
| SCHEMBL28093877 | 0.87 | TDP1 (0.47) | TDP1GAALMNASMN1; SMN2TSHR | |
| SCHEMBL7259428 | 0.87 | TDP1 (0.47) | TDP1GAALMNASMN1; SMN2TSHR | |
| SCHEMBL3225523 | 0.86 | TSHR (0.51) | TDP1GAALMNATSHRALDH1A1 | |
| SCHEMBL10013500 | 0.85 | TSHR (0.56) | TDP1GAALMNATSHRALDH1A1 | |
| SCHEMBL1515826 | 0.84 | CYP4F2 (0.62) | TDP1GAALMNASMN1; SMN2TSHR | |
| SCHEMBL7888534 | 0.83 | CYP1A2 (0.52) | TDP1GAALMNATSHRALDH1A1 | |
| SCHEMBL6471980 | 0.82 | TDP1 (0.44) | TDP1GAALMNASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112209825-B | Synthetic method of 3-ethoxy-4-ethoxycarbonylphenylacetic acid | 江苏八巨药业有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-112209825-A | Synthetic method of 3-ethoxy-4-ethoxycarbonylphenylacetic acid | 江苏八巨药业有限公司 | 2021-01-12 | — | — | CN | claimed |
| CN-105198838-A | Preparation method of repaglinide | Henan purui pharmaceutical co ltd | 2015-12-30 | — | — | CN | claimed |
| CN-104628518-A | Method for synthesizing repaglinide key intermediate | HUBEI YITAI PHARMACEUTICAL CO LTD | 2015-05-20 | — | — | CN | claimed |
| CN-101891621-B | Compounding method for 3- ethyoxyl-4-ethoxycarbonyl phenylacetic acid | QIDONG HUDONG CHEMICAL CO LTD | 2015-05-13 | — | — | CN | claimed |
| CN-103880679-B | Synthesis method of 3- ethyoxyl-4-ethoxycarbonyl phenylacetic acid | UNIV HEBEI SCIENCE & TECH | 2015-02-11 | — | — | CN | claimed |
| CN-103880679-A | Synthesis method of 3- ethyoxyl-4-ethoxycarbonyl phenylacetic acid | UNIV HEBEI SCIENCE & TECH | 2014-06-25 | — | — | CN | claimed |
| CN-102766112-B | Synthetic method of repaglinide | HEBEI FUGE PHARMACY CO LTD | 2014-03-19 | — | — | CN | claimed |
| CN-102731311-A | Method for preparing 4-ethoxycarbonyl-3-ethoxybenzeneacetic acid | TIANJIN JIAFAN BIOLOG TECHNOLOGY CO LTD | 2012-10-17 | — | — | CN | claimed |
| CN-102633750-A | One-pot method for synthesizing repaglinide for treating diabetes | Zhejiang anglikang pharmaceutical co ltd | 2012-08-15 | — | — | CN | claimed |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | ACTAVIS GROUP PTC EHF (IS) | 2010-08-05 | — | — | US | claimed |
| EP-2155706-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | Actavis Group PTC EHF (IS) | 2010-02-24 | — | — | EP | claimed |
| WO-2009004485-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2009-01-08 | — | — | WO | claimed |
| CN-101153010-A | Novel method of producing repaglinide key intermediate | BEIJING DEZHONG WANQUAN MEDICINE TECHNOLOGY DEV CO LTD (CN) | 2008-04-02 | — | — | CN | claimed |
| EP-1751084-A2 | SYNTHESIS OF 3-ETHOXY-4-ETHOXYCARBONYL PHENYL ACETIC ACID, A KEY ACID SYNTHON OF REPAGLINIDE | RANBAXY LABORATORIES, LTD. (IN) | 2007-02-14 | — | — | EP | claimed |
| WO-2005019140-A1 | ETHYL 4-(2-TERT-BUTOXY-2-OXOETHYL)-2-ETHOXYBENZOATE, INTERMEDIATE FOR THE PREPARATION OF REPAGLINIDE | BIOCON LIMITED (IN) | 2005-03-03 | — | — | WO | claimed |
| US-6686497-B1 | TO AVOID THE USE OF HAZARDOUS, TOXIC AND COMMERCIALLY DIFFICULT-TO-HANDLE RAW MATERIALS IN PREPARATION OF HYPOGLYCEMIC AGENTS | BANBAXY LABORATORIES LIMITED (IN) | 2004-02-03 | — | — | US | claimed |
| EP-0965591-B1 | Process for the preparation of (S)-3-methyl-1-(2-piperidino-phenyl)-1-butylamine | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-09-04 | — | — | EP | claimed |
| WO-2001035900-A2 | SYNTHESIS OF 3-ETHOXY-4-ETHOXYCARBONYL PHENYL ACETIC ACID, A KEY ACID SYNTHON OF REPAGLINIDE | RANBAXY LABORATORIES LIMITED (IN) | 2001-05-25 | — | — | WO | claimed |
| CN-115073383-B | Synthesis method of aryl acetic acid compound | 四川大学 | 2023-07-18 | — | — | CN | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| CN-115073383-A | Synthetic method of aryl acetic acid compound | 四川大学 | 2022-09-20 | — | — | CN | disclosed |
| CN-112209825-B | Synthetic method of 3-ethoxy-4-ethoxycarbonylphenylacetic acid | 江苏八巨药业有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-112209825-B | Synthetic method of 3-ethoxy-4-ethoxycarbonylphenylacetic acid | 江苏八巨药业有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-112209825-B | Synthetic method of 3-ethoxy-4-ethoxycarbonylphenylacetic acid | 江苏八巨药业有限公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021126999-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126999-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3189041-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-04-28 | — | — | EP | disclosed |
| EP-3189041-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-04-28 | — | — | EP | disclosed |
| EP-3189048-B1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-03-17 | — | — | EP | disclosed |
| CN-112209825-A | Synthetic method of 3-ethoxy-4-ethoxycarbonylphenylacetic acid | 江苏八巨药业有限公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-112209825-A | Synthetic method of 3-ethoxy-4-ethoxycarbonylphenylacetic acid | 江苏八巨药业有限公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-112209825-A | Synthetic method of 3-ethoxy-4-ethoxycarbonylphenylacetic acid | 江苏八巨药业有限公司 | 2021-01-12 | — | — | CN | disclosed |
| EP-3214077-B1 | PROCESS FOR THE PURIFICATION OF A PHARMACEUTICAL AGENT | ZAKL FARMACEUTYCZNE POLPHARMA S A (PL) | 2020-03-11 | — | — | EP | disclosed |
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | CTXT PTY. LTD. (AU) | 2018-06-26 | — | — | US | disclosed |
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | CTXT PTY. LTD. (AU) | 2018-06-26 | — | — | US | disclosed |
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | CTXT PTY. LTD. (AU) | 2018-06-26 | — | — | US | disclosed |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-11-02 | — | — | US | disclosed |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-11-02 | — | — | US | disclosed |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-11-02 | — | — | US | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| EP-3214077-A1 | PROCESS FOR THE PURIFICATION OF A PHARMACEUTICAL AGENT | Zaklady Farmaceutyczne "Polpharma" S.A. (PL) | 2017-09-06 | — | — | EP | disclosed |
| EP-3189048-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | Ctxt Pty Ltd (AU) | 2017-07-12 | — | — | EP | disclosed |
| EP-3189041-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | Ctxt Pty Ltd (AU) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034671-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034671-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| CN-105198838-A | Preparation method of repaglinide | Henan purui pharmaceutical co ltd | 2015-12-30 | — | — | CN | disclosed |
| CN-105198838-A | Preparation method of repaglinide | Henan purui pharmaceutical co ltd | 2015-12-30 | — | — | CN | disclosed |
| CN-105175361-A | Improved production process for repaglinide | TIANJIN PHARMACEUTICAL GROUP GENCOM PHARMACEUTICAL | 2015-12-23 | — | — | CN | disclosed |
| WO-2015135096-A1 | METHOD FOR SYNTHESIZING 3-ETHOXY-4-ETHOXYCARBONYL PHENYLACETIC ACID | 河北科技大学 | 2015-09-17 | — | — | WO | disclosed |
| CN-104628518-A | Method for synthesizing repaglinide key intermediate | HUBEI YITAI PHARMACEUTICAL CO LTD | 2015-05-20 | — | — | CN | disclosed |
| CN-101891621-B | Compounding method for 3- ethyoxyl-4-ethoxycarbonyl phenylacetic acid | QIDONG HUDONG CHEMICAL CO LTD | 2015-05-13 | — | — | CN | disclosed |
| CN-104557778-A | Preparation method and application of repaglinide | CAI LUN | 2015-04-29 | — | — | CN | disclosed |
| CN-101830796-B | Preparation method of 3-ethyoxyl-4-carboxylphenylacetic acid | BEIJING HUAXI LIANHE TECHNOLOGY DEV CO LTD | 2015-02-18 | — | — | CN | disclosed |
| CN-103880679-B | Synthesis method of 3- ethyoxyl-4-ethoxycarbonyl phenylacetic acid | UNIV HEBEI SCIENCE & TECH | 2015-02-11 | — | — | CN | disclosed |
| CN-103880679-A | Synthesis method of 3- ethyoxyl-4-ethoxycarbonyl phenylacetic acid | UNIV HEBEI SCIENCE & TECH | 2014-06-25 | — | — | CN | disclosed |
| CN-102766112-B | Synthetic method of repaglinide | HEBEI FUGE PHARMACY CO LTD | 2014-03-19 | — | — | CN | disclosed |
| CN-103193652-A | Method for preparing repaglinide intermediate | TIANJIN JIAFAN BIOLOG TECHNOLOGY CO LTD | 2013-07-10 | — | — | CN | disclosed |
| CN-102070433-B | Preparation method for aryl acetic acid derivative | GUILIN NORMAL COLLEGE | 2013-03-27 | — | — | CN | disclosed |
| CN-102731311-A | Method for preparing 4-ethoxycarbonyl-3-ethoxybenzeneacetic acid | TIANJIN JIAFAN BIOLOG TECHNOLOGY CO LTD | 2012-10-17 | — | — | CN | disclosed |
| CN-102731311-A | Method for preparing 4-ethoxycarbonyl-3-ethoxybenzeneacetic acid | TIANJIN JIAFAN BIOLOG TECHNOLOGY CO LTD | 2012-10-17 | — | — | CN | disclosed |
| CN-102731311-A | Method for preparing 4-ethoxycarbonyl-3-ethoxybenzeneacetic acid | TIANJIN JIAFAN BIOLOG TECHNOLOGY CO LTD | 2012-10-17 | — | — | CN | disclosed |
| EP-2488491-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| CN-102633750-A | One-pot method for synthesizing repaglinide for treating diabetes | Zhejiang anglikang pharmaceutical co ltd | 2012-08-15 | — | — | CN | disclosed |
| CN-102633750-A | One-pot method for synthesizing repaglinide for treating diabetes | Zhejiang anglikang pharmaceutical co ltd | 2012-08-15 | — | — | CN | disclosed |
| US-8198054-B2 | Method for the chemo-selective enzymatic hydrolysis if a diester compound for preparing a monoester monoacid compound | ZACH SYSTEM (FR) | 2012-06-12 | — | — | US | disclosed |
| US-20120065404-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2012-03-15 | — | — | US | disclosed |
| US-8101769-B2 | Chemical intermediate; high purity drug | ACTAVIS GROUP PTC EHF (IE) | 2012-01-24 | — | — | US | disclosed |
| US-8017607-B2 | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-2358369-A1 | Process for the preparation of substantially optically pure repaglinide and precursors thereof | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011045257-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086854-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | BARTKOVITZ DAVID JOSEPH | 2011-04-14 | — | — | US | disclosed |
| US-7915421-B2 | Method for preparing phenyl acetic acid derivatives | CILAG LTD. (CH) | 2011-03-29 | — | — | US | disclosed |
| US-7829567-B2 | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-09 | — | — | US | disclosed |
| CN-101830796-A | Preparation method of 3-ethyoxyl-4-carboxylphenylacetic acid | HUAXIPHARM CO LTD | 2010-09-15 | — | — | CN | disclosed |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | ACTAVIS GROUP PTC EHF (IS) | 2010-08-05 | — | — | US | disclosed |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | ACTAVIS GROUP PTC EHF (IS) | 2010-08-05 | — | — | US | disclosed |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | ACTAVIS GROUP PTC EHF (IS) | 2010-08-05 | — | — | US | disclosed |
| US-20100179137-A1 | PYRIDONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-15 | — | — | US | disclosed |
| WO-2010046360-A1 | PROCESS FOR THE PREPARATION OF SUBSTANTIALLY OPTICALLY PURE REPAGLINIDE AND PRECURSORS THEREOF | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2010-04-29 | — | — | WO | disclosed |
| EP-2177221-A1 | Process for the preparation of substantially optically pure Repaglinide and precursors thereof | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2010-04-21 | — | — | EP | disclosed |
| US-20100068770-A1 | METHOD FOR THE CHEMO-SELECTIVE ENZYMATIC HYDROLYSIS IF A DIESTER COMPOUND FOR PREPARING A MONOESTER MONOACID COMPOUND | ZACH SYSTEM (FR) | 2010-03-18 | — | — | US | disclosed |
| EP-2155706-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | Actavis Group PTC EHF (IS) | 2010-02-24 | — | — | EP | disclosed |
| EP-2154130-A1 | PYRIDONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-02-17 | — | — | EP | disclosed |
| EP-2121644-A2 | IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE | Actavis Group PTC EHF (IS) | 2009-11-25 | — | — | EP | disclosed |
| US-20090209587-A1 | REPAGLINIDE FORMULATIONS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-08-20 | — | — | US | disclosed |
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-04-30 | — | — | US | disclosed |
| WO-2009004485-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009004485-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2009-01-08 | — | — | WO | disclosed |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2008-08-21 | — | — | US | disclosed |
| WO-2008099286-A2 | IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE | ACTAVIS GROUP PTC EHF (US) | 2008-08-21 | — | — | WO | disclosed |
| CN-101153010-A | Novel method of producing repaglinide key intermediate | BEIJING DEZHONG WANQUAN MEDICINE TECHNOLOGY DEV CO LTD (CN) | 2008-04-02 | — | — | CN | disclosed |
| CN-101153010-A | Novel method of producing repaglinide key intermediate | BEIJING DEZHONG WANQUAN MEDICINE TECHNOLOGY DEV CO LTD (CN) | 2008-04-02 | — | — | CN | disclosed |
| CN-100368375-C | 3- alkoxy -4-carbalkoxyphenylacetate and 3-alkoxy-4-carbalkoxyphenylacetic acid synthesis method | ZHEJIANG HAIXIANG PHARMACEUTIC (CN) | 2008-02-13 | — | — | CN | disclosed |
| US-20070123564-A1 | Method for preparing phenyl acetic acid derivatives | CILAG LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| EP-1751084-A2 | SYNTHESIS OF 3-ETHOXY-4-ETHOXYCARBONYL PHENYL ACETIC ACID, A KEY ACID SYNTHON OF REPAGLINIDE | RANBAXY LABORATORIES, LTD. (IN) | 2007-02-14 | — | — | EP | disclosed |
| EP-1751084-A2 | SYNTHESIS OF 3-ETHOXY-4-ETHOXYCARBONYL PHENYL ACETIC ACID, A KEY ACID SYNTHON OF REPAGLINIDE | RANBAXY LABORATORIES, LTD. (IN) | 2007-02-14 | — | — | EP | disclosed |
| US-7148355-B2 | Process for the preparation of repaglinide | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-12 | — | — | US | disclosed |
| CN-1800139-A | 3- alkoxy -4-carbalkoxyphenylacetate and 3-alkoxy-4-carbalkoxyphenylacetic acid synthesis method | ZHEJIANG HAIXIANG PHARMACEUTIC (CN) | 2006-07-12 | — | — | CN | disclosed |
| EP-1636199-A2 | METHOD FOR THE PRODUCTION OF PHENYLACETIC ACID DERIVATIVES | Cilag AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| EP-1432682-B1 | PROCESS FOR THE PREPARATION OF REPAGLINIDE | RANBAXY LAB LTD (IN) | 2005-05-25 | — | — | EP | disclosed |
| US-20050107614-A1 | Process for the preparation of repaglinide | RANBAXY LABORATORIES LIMITED (IN) | 2005-05-19 | — | — | US | disclosed |
| WO-2005019140-A1 | ETHYL 4-(2-TERT-BUTOXY-2-OXOETHYL)-2-ETHOXYBENZOATE, INTERMEDIATE FOR THE PREPARATION OF REPAGLINIDE | BIOCON LIMITED (IN) | 2005-03-03 | — | — | WO | disclosed |
| US-20040249188-A1 | Process for the preparation of 3-ethoxy-4-(alkoxy carbonyl)-phenyl acetic acid. (an intermediate of repaglinide) | DR. REDDY'S LABORATORIES LIMITED | 2004-12-09 | — | — | US | disclosed |
| WO-2004103983-A1 | PROCESS FOR THE PREPARATION OF S(+)-2-ETHOXY-4-[N-{1-(2-PIPERIDINOPHELYL)-3-METHYL-1- BUTYL} AMINOCARBONYLMETHYL]BENZOIC ACID DERIVATIVES | BIOCON LIMITED (IN) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004101540-A2 | METHOD FOR THE PRODUCTION OF PHENYLACETIC ACID DERIVATIVES | CILAG AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| US-6818786-B2 | REACTING 4-METHYLSALICYLIC ACID WITH DIETHYL SULFATE IN POLAR ORGANIC SOLVENT AND POTASSIUM CARBONATE, BROMINATING ETHYL 2-ETHOXY-4-METHYLBENZOATE IN ORGANIC SOLVENT, REACTING ETHYL 4-BROMOMETHYL-2-ETHOXY BENZOATE WITH CARBON MONOXIDE/ETHANOL | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-11-16 | — | — | US | disclosed |
| US-20040192955-A1 | PROCESS FOR THE PREPARATION OF ETHYL 3-ETHOXY-4-ETHOXYCARBONYL-PHENYLACETATE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-09-30 | — | — | US | disclosed |
| EP-1432682-A1 | PROCESS FOR THE PREPARATION OF REPAGLINIDE | RANBAXY LABORATORIES, LTD. (IN) | 2004-06-30 | — | — | EP | disclosed |
| US-20040102477-A1 | Antidiabetic agents | DR. REDDY'S LABORATORIES LIMITED | 2004-05-27 | — | — | US | disclosed |
| WO-2004018442-A1 | CRYSTALLINE AND AMORPHOUS FORMS OF (S) -REPAGLINIDE AND THE PROCESSES FOR PREPARATION THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2004-03-04 | — | — | WO | disclosed |
| US-6686497-B1 | TO AVOID THE USE OF HAZARDOUS, TOXIC AND COMMERCIALLY DIFFICULT-TO-HANDLE RAW MATERIALS IN PREPARATION OF HYPOGLYCEMIC AGENTS | BANBAXY LABORATORIES LIMITED (IN) | 2004-02-03 | — | — | US | disclosed |
| US-6686497-B1 | TO AVOID THE USE OF HAZARDOUS, TOXIC AND COMMERCIALLY DIFFICULT-TO-HANDLE RAW MATERIALS IN PREPARATION OF HYPOGLYCEMIC AGENTS | BANBAXY LABORATORIES LIMITED (IN) | 2004-02-03 | — | — | US | disclosed |
| US-6686497-B1 | TO AVOID THE USE OF HAZARDOUS, TOXIC AND COMMERCIALLY DIFFICULT-TO-HANDLE RAW MATERIALS IN PREPARATION OF HYPOGLYCEMIC AGENTS | BANBAXY LABORATORIES LIMITED (IN) | 2004-02-03 | — | — | US | disclosed |
| WO-2003087059-A2 | (E)-OXIME ETHER DERIVATIVE OF 5,6-DIHYDRO-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-ONE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003027072-A1 | PROCESS FOR THE PREPARATION OF REPAGLINIDE | RANBAXY LABORATORIES LIMITED (IN) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003011835-A1 | BENZIMIDAZOLYLALKYL-ARYL(ALKAN) OIC ACID DERIVATIVES AND THEIR USE AS ANTIHYPERGLYCAEMICS | MERCK PATENT GMBH (DE) | 2003-02-13 | — | — | WO | disclosed |
| EP-0965591-B1 | Process for the preparation of (S)-3-methyl-1-(2-piperidino-phenyl)-1-butylamine | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001035900-A3 | SYNTHESIS OF 3-ETHOXY-4-ETHOXYCARBONYL PHENYL ACETIC ACID, A KEY ACID SYNTHON OF REPAGLINIDE | RANBAXY LAB LTD (IN) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001035900-A2 | SYNTHESIS OF 3-ETHOXY-4-ETHOXYCARBONYL PHENYL ACETIC ACID, A KEY ACID SYNTHON OF REPAGLINIDE | RANBAXY LABORATORIES LIMITED (IN) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001035900-A2 | SYNTHESIS OF 3-ETHOXY-4-ETHOXYCARBONYL PHENYL ACETIC ACID, A KEY ACID SYNTHON OF REPAGLINIDE | RANBAXY LABORATORIES LIMITED (IN) | 2001-05-25 | — | — | WO | disclosed |
| US-RE37035-E1 | HYPOGLYCEMIC AGENTS | BOEHRINGER INGELHEIM KG (DE) | 2001-01-30 | — | — | US | disclosed |
| US-6143769-A | ENANTIOMORPH | KARL THOMAE GMBH (DE) | 2000-11-07 | — | — | US | disclosed |
| EP-0965591-A1 | (s)-3-methyl-1-(2-piperidino-phenyl)-1-butylamine, its salts, synthesis and use in the long term therapy of diabetes mellitus | Boehringer Ingelheim Pharma KG (DE) | 1999-12-22 | — | — | EP | disclosed |
| EP-0589874-B1 | USE OF (S)(+)-2-ETHOXY-4-[N-[1-(2-PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYLMETHYL]BENZOIC ACID FOR THE PREPARATION OF A LONGLASTING ANTIDIABETIC MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-09-08 | — | — | EP | disclosed |
| US-5312924-A | Compounds for lowering blood sugar and effecting metabolism | DR. KARL THOMAE GMBH (DE) | 1994-05-17 | — | — | US | disclosed |
| EP-0589874-A1 | (S)(+)-2-ETHOXY-4- N- 1-(2-PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYLMETHYL]BENZOIC ACID | Dr. Karl Thomae GmbH (DE) | 1994-04-06 | — | — | EP | disclosed |
| US-5216167-A | Hypoglycemic agents | DR. KARL THOMAE GMBH (DE) | 1993-06-01 | — | — | US | disclosed |
| WO-1993000337-A1 | (S)(+)-2-ETHOXY-4-[N-[1-(2-PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYLMETHYL]BENZOIC ACID | DR. KARL THOMAE GMBH (DE) | 1993-01-07 | — | — | WO | disclosed |
| EP-0207331-B1 | Solid forms of 2-ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-amino-carbonylmethyl]-benzoic acid, medicaments containing these forms and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-05-23 | — | — | EP | disclosed |
| EP-0208200-B1 | PHENYLACETIC-ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1990-04-25 | — | — | EP | disclosed |
| EP-0147850-B1 | PHENYLACETIC-ACID DERIVATIVES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | Dr. Karl Thomae GmbH (DE) | 1989-06-14 | — | — | EP | disclosed |
| EP-0208200-A1 | Phenylacetic-acid derivatives, pharmaceutical compositions containing them and processes for their production | Dr. Karl Thomae GmbH (DE) | 1987-01-14 | — | — | EP | disclosed |
| EP-0207331-A1 | Solid forms of 2-ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-amino-carbonylmethyl]-benzoic acid, medicaments containing these forms and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1987-01-07 | — | — | EP | disclosed |
| EP-0147850-A2 | Phenylacetic-acid derivatives, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-07-10 | — | — | EP | disclosed |
| EP-0147850-A2 | Phenylacetic-acid derivatives, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | PRMT5, PRMT1, PRMT3 | TDP1 1654/4885GAA 4881/4885LMNA 2011/4885 |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | TDP1 1710/4885GAA 4881/4885LMNA 2112/4885 |
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | IMPA1, IMPDH1, IPO5 | TDP1 2258/4885GAA 2604/4885LMNA 714/4885 |
| US-20090209587-A1 | REPAGLINIDE FORMULATIONS | GCG, GCGR, GLP1R | TDP1 2280/4885GAA 150/4885LMNA 3855/4885 |
| US-20050107614-A1 | Process for the preparation of repaglinide | GCG, GCGR, GID4 | TDP1 2700/4885GAA 20/4885LMNA 2884/4885 |
| US-20100179137-A1 | PYRIDONE COMPOUND | PTGER4, P2RY4, PTGER1 | TDP1 3430/4885GAA 4825/4885LMNA 4245/4885 |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | TDP1 2047/4885GAA 4858/4885LMNA 1558/4885 |
| US-20110086854-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | MDM2, TP53, TP53BP1 | TDP1 575/4885GAA 2559/4885LMNA 2135/4885 |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | EMG1, DAP3, DRD4 | TDP1 941/4885GAA 2187/4885LMNA 1901/4885 |
| US-20070123564-A1 | Method for preparing phenyl acetic acid derivatives | PHF2, ASF1A, NAT1 | TDP1 461/4885GAA 349/4885LMNA 598/4885 |
| US-20120065404-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | MEP1B, GABRE, BPGM | TDP1 1622/4885GAA 48/4885LMNA 2050/4885 |
| US-20040102477-A1 | Antidiabetic agents | GPR119, IAPP, GCG | TDP1 3713/4885GAA 18/4885LMNA 3140/4885 |
| US-20040249188-A1 | Process for the preparation of 3-ethoxy-4-(alkoxy carbonyl)-phenyl acetic acid. (an intermediate of repaglinide) | ALDH1A1, ADRM1, ALDH7A1 | TDP1 1135/4885GAA 93/4885LMNA 2747/4885 |
| US-20040192955-A1 | PROCESS FOR THE PREPARATION OF ETHYL 3-ETHOXY-4-ETHOXYCARBONYL-PHENYLACETATE | DPP4, GLP1R, SLC2A4 | TDP1 3020/4885GAA 39/4885LMNA 2875/4885 |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | MEP1B, GABRE, BPGM | TDP1 1622/4885GAA 48/4885LMNA 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.